Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2- Breast Cancer Based on a Window of Opportunity Study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36135204/
1 Department of Biology and Biochemistry, University of Bath, Bath BA2 7 AY, UK. 2 Department of Biostatistics and Epidemiology, Gustave Roussy, Paris-Saclay University, 91190 Gif-sur-Yvette, France. 3 Department of Medicine, The Princess Alexandra Hospital, Harlow CM20 1 QX, UK. 4 Milner Centre for Evolution, Department of Biology and Biochemistry, University of Bath, Bath BA2 7 AY, UK.
Conclusions: Our study strongly supports the notion that CDK4/6 inhibitors induce tumour immune modulation. N/L ratio and platelet levels decreased due to treatment. Future studies should test whether patients would benefit from immunomodulators in association with CDK4/6 agents in a larger clinical trial. Moreover, the CDK4/6-induced immune modulation could also be considered a potential predictive clinical factor in HR /HER2- advanced breast cancer.